Table 1.
All characteristics of patients with nontraumatic cerebral hemorrhage
| Characteristics | Overall | Q1 | Q2 | Q3 | Q4 | P |
|---|---|---|---|---|---|---|
| n | 537 | 135 | 135 | 134 | 133 | |
| In-hospital death = Yes (%) | 99 (18.4) | 12 (8.9) | 24 (17.8) | 18 (13.4) | 45 (33.8) | < 0.001 |
| Hospital stays (day) |
8.00 [4.00, 16.00] |
7.00 [4.00, 12.00] |
8.00 [4.00, 13.50] |
8.00 [5.00, 17.00] |
10.00 [4.00, 22.00] |
0.039 |
| GCS score < 8 (%) | 48 (8.9) | 5 (3.7) | 13 (9.6) | 11 (8.2) | 19 (14.3) | 0.025 |
| Follow-up time of GCS score |
7.00 [4.00, 14.00] |
7.00 [4.00, 11.50] |
6.00 [3.00, 12.00] |
7.00 [4.00, 15.00] |
8.00 [4.00, 19.00] |
0.131 |
| Gender = Male (%) | 293 (54.6) | 67 (49.6) | 77 (57.0) | 75 (56.0) | 74 (55.6) | 0.609 |
| Race (%) | 0.215 | |||||
| Asian | 14 (2.6) | 2 (1.5) | 3 (2.2) | 5 (3.7) | 4 (3.0) | |
| Black | 51 (9.5) | 15 (11.1) | 16 (11.9) | 10 (7.5) | 10 (7.5) | |
| Other | 165 (30.7) | 31 (23.0) | 37 (27.4) | 47 (35.1) | 50 (37.6) | |
| White | 307 (57.2) | 87 (64.4) | 79 (58.5) | 72 (53.7) | 69 (51.9) | |
| Anemia = Yes (%) | 103 (19.2) | 18 (13.3) | 24 (17.8) | 30 (22.4) | 31 (23.3) | 0.139 |
| Cancer = Yes (%) | 42 (7.8) | 11 (8.1) | 9 (6.7) | 10 (7.5) | 12 (9.0) | 0.906 |
| CKD = Yes (%) | 92 (17.1) | 17 (12.6) | 23 (17.0) | 26 (19.4) | 26 (19.5) | 0.393 |
| Diabetes = Yes (%) | 154 (28.7) | 17 (12.6) | 36 (26.7) | 39 (29.1) | 62 (46.6) | < 0.001 |
| Hyperlipemia = Yes (%) | 37 (6.9) | 8 (5.9) | 9 (6.7) | 11 (8.2) | 9 (6.8) | 0.903 |
| Hypertension = Yes (%) | 449 (83.6) | 107 (79.3) | 121 (89.6) | 117 (87.3) | 104 (78.2) | 0.022 |
| Respiratory failure = Yes (%) | 51 (9.5) | 9 (6.7) | 6 (4.4) | 15 (11.2) | 21 (15.8) | 0.008 |
| Site (%) | 0.029 | |||||
| cerebellum | 30 (5.6) | 9 (6.7) | 8 (5.9) | 5 (3.7) | 8 (6.0) | |
| cortical | 121 (22.5) | 35 (25.9) | 34 (25.2) | 27 (20.1) | 25 (18.8) | |
| intraventricular | 79 (14.7) | 17 (12.6) | 15 (11.1) | 23 (17.2) | 24 (18.0) | |
| Other | 216 (40.2) | 57 (42.2) | 62 (45.9) | 54 (40.3) | 43 (32.3) | |
| subarachnoid | 61 (11.4) | 6 (4.4) | 11 (8.1) | 19 (14.2) | 25 (18.8) | |
| subdural | 30 (5.6) | 11 (8.1) | 5 (3.7) | 6 (4.5) | 8 (6.0) | |
| Alcohol abuse = Yes (%) | 56 (10.4) | 10 (7.4) | 6 (4.4) | 23 (17.2) | 17 (12.8) | 0.003 |
| Long-term use of antiplatelet agents/anticoagulants = Yes (%) | 123 (22.9) | 30 (22.2) | 36 (26.7) | 30 (22.4) | 27 (20.3) | 0.648 |
| Tobacco use = Yes (%) | 6 (1.1) | 0 (0.0) | 1 (0.7) | 3 (2.2) | 2 (1.5) | 0.333 |
| BMI (%) | ||||||
| < 18 | 6 (1.1) | 1 (0.7) | 1 (0.7) | 2 (1.5) | 2 (1.5) | 0.874 |
| > 24 | 143 (26.6) | 41 (30.4) | 38 (28.1) | 26 (19.4) | 38 (28.6) | 0.174 |
| 18–24 | 44 (8.2) | 17 (12.6) | 11 (8.1) | 10 (7.5) | 6 (4.5) | 0.113 |
| CPK (%) | ||||||
| ≤ 130 IU/L | 161 (30.0) | 44 (32.6) | 40 (29.6) | 44 (32.8) | 33 (24.8) | 0.447 |
| > 130 IU/L | 171 (31.8) | 39 (28.9) | 44 (32.6) | 35 (26.1) | 53 (39.8) | 0.089 |
| CKMB (%) | ||||||
| > 5 ng/mL | 78 (14.5) | 11 (8.1) | 17 (12.6) | 20 (14.9) | 30 (22.6) | 0.008 |
| ≤ 5 ng/mL | 223 (41.5) | 61 (45.2) | 60 (44.4) | 53 (39.6) | 49 (36.8) | 0.451 |
| IDH (%) | ||||||
| ≤ 300 IU/L | 244 (45.4) | 71 (52.6) | 63 (46.7) | 56 (41.8) | 54 (40.6) | 0.184 |
| > 300 IU/L | 98 (18.2) | 15 (11.1) | 19 (14.1) | 26 (19.4) | 38 (28.6) | 0.001 |
| CRP (%) | ||||||
| ≤ 5 mg/L | 49 (9.1) | 18 (13.3) | 13 (9.6) | 10 (7.5) | 8 (6.0) | 0.178 |
| > 10 mg/L | 69 (12.8) | 16 (11.9) | 14 (10.4) | 17 (12.7) | 22 (16.5) | 0.478 |
| 5–10 mg/L | 22 (4.1) | 3 (2.2) | 10 (7.4) | 4 (3.0) | 5 (3.8) | 0.143 |
| HbA 1c (%) | < 0.001 | |||||
| 4–6% | 334 (62.2) | 112 (83.0) | 92 (68.1) | 79 (59.0) | 51 (38.3) | |
| > 6% | 203 (37.8) | 23 (17.0) | 43 (31.9) | 55 (41.0) | 82 (61.7) | |
| Age (%) | < 0.001 | |||||
| < 40 years | 20 (3.7) | 5 (3.7) | 3 (2.2) | 5 (3.7) | 7 (5.3) | |
| ≥ 80 years | 131 (24.4) | 49 (36.3) | 36 (26.7) | 26 (19.4) | 20 (15.0) | |
| 40–59 years | 100 (18.6) | 20 (14.8) | 12 (8.9) | 31 (23.1) | 37 (27.8) | |
| 60–79 years | 286 (53.3) | 61 (45.2) | 84 (62.2) | 72 (53.7) | 69 (51.9) | |
| ALP (%) | 0.003 | |||||
| < 40 IU/L | 13 (2.4) | 4 (3.0) | 5 (3.7) | 0 (0.0) | 4 (3.0) | |
| > 130 IU/L | 65 (12.1) | 7 (5.2) | 14 (10.4) | 17 (12.7) | 27 (20.3) | |
| 40–130 IU/L | 459 (85.5) | 124 (91.9) | 116 (85.9) | 117 (87.3) | 102 (76.7) | |
| AST (%) | 0.003 | |||||
| ≤ 40 IU/L | 384 (71.5) | 110 (81.5) | 101 (74.8) | 90 (67.2) | 83 (62.4) | |
| >40 IU/L | 153 (28.5) | 25 (18.5) | 34 (25.2) | 44 (32.8) | 50 (37.6) | |
| Creatinine (%) | 0.007 | |||||
| < 0.5 mg/dL | 9 (1.7) | 3 (2.2) | 1 (0.7) | 2 (1.5) | 3 (2.3) | |
| > 1.2 mg/dL | 108 (20.1) | 17 (12.6) | 21 (15.6) | 29 (21.6) | 41 (30.8) | |
| 0.5–1.2 mg/dL | 420 (78.2) | 115 (85.2) | 113 (83.7) | 103 (76.9) | 89 (66.9) | |
| INR (%) | 0.859 | |||||
| 0.9–1.1 | 285 (53.1) | 75 (55.6) | 71 (52.6) | 72 (53.7) | 67 (50.4) | |
| > 1.1 | 252 (46.9) | 60 (44.4) | 64 (47.4) | 62 (46.3) | 66 (49.6) | |
| PT (%) | 0.094 | |||||
| < 11 s | 49 (9.1) | 11 (8.1) | 7 (5.2) | 21 (15.7) | 10 (7.5) | |
| > 13 s | 183 (34.1) | 50 (37.0) | 46 (34.1) | 40 (29.9) | 47 (35.3) | |
| 11–13 s | 305 (56.8) | 74 (54.8) | 82 (60.7) | 73 (54.5) | 76 (57.1) | |
| PTT (%) | 0.263 | |||||
| < 25 s | 81 (15.1) | 17 (12.6) | 17 (12.6) | 20 (14.9) | 27 (20.3) | |
| > 37 s | 35 (6.5) | 13 (9.6) | 6 (4.4) | 7 (5.2) | 9 (6.8) | |
| 25–37 s | 421 (78.4) | 105 (77.8) | 112 (83.0) | 107 (79.9) | 97 (72.9) | |
| ALT (%) | < 0.001 | |||||
| ≤ 40 IU/L (%) | 444 (82.7) | 122 (90.4) | 119 (88.1) | 108 (80.6) | 95 (71.4) | |
| >40 IU/L (%) | 93 (17.3) | 13 (9.6) | 16 (11.9) | 26 (19.4) | 38 (28.6) |
TyG index: Q1 (7.129–8.378), Q2 (8.378–8.764), Q3 (8.764–9.239), Q4 (9.239–12.102)